Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Maheswaran

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The Journal of Bone and Joint Surgery. American Volume|November 8, 2013
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K)Sattar Alshryda, James Mason, Manesh Vaghela, et al.
The Journal of Biological Chemistry|August 26, 2000
Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanismT U Ha, D L Segev, D Barbie, et al.
Cell|June 15, 1999
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1D P Harkin, J M Bean, D Miklos, et al.
Genes & Development|May 30, 1998
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70S Maheswaran, C Englert, G Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MISP T Masiakos, D T MacLaughlin, S Maheswaran, et al.
Oncogene|October 11, 2001
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agentsP B Mullan, J E Quinn, P M Gilmore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2023
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialL M Spring, S M Tolaney, G Fell, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Journal of Bone and Joint Surgery. American Volume|November 8, 2013
Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K)Sattar Alshryda, James Mason, Manesh Vaghela, et al.
The Journal of Biological Chemistry|August 26, 2000
Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanismT U Ha, D L Segev, D Barbie, et al.
Cell|June 15, 1999
Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1D P Harkin, J M Bean, D Miklos, et al.
Genes & Development|May 30, 1998
Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70S Maheswaran, C Englert, G Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MISP T Masiakos, D T MacLaughlin, S Maheswaran, et al.
Oncogene|October 11, 2001
BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agentsP B Mullan, J E Quinn, P M Gilmore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2023
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialL M Spring, S M Tolaney, G Fell, et al.
Pageof 4